Zealand Pharma A/S – American Depositary Shares (NASDAQ:ZEAL) Shorted Shares Increased By 9.18%

June 29, 2018 - By Andre Harris

It was recorded an increase on Zealand Pharma A/S – American Depositary Shares (NASDAQ:ZEAL)’s short interest with 9.18%. FINRA published short interest of ZEAL’s total 254,500 shares. That’s 9.18% up from 233,100 shares. With Average volume 6,100, ZEAL’s former position will take 42 days to restore. 1.1% is Zealand Pharma A/S – American Depositary Shares float short.

ZEAL hit $13 during the last trading session after $0.07 change.Currently Zealand Pharma A/S is after 0.00% change in last June 29, 2017. ZEAL has 3,000 shares volume. ZEAL underperformed the S&P 500 by 12.57%.

Zealand Pharma A/S, a biotechnology company, engages in the discovery, design, and development of peptide therapeutics medicines in Denmark.The firm is worth $424.62 million. It has a portfolio of proprietary medicines in late-stage clinical development focusing on gastrointestinal and metabolic diseases.Last it reported negative earnings. The firm markets lixisenatide for the treatment of type 2 diabetes under the brand names of Adlyxin and Lyxumia; and a combination of lixisenatide and insulin glargine for the treatment of type 2 diabetes under the brand names of Soliqua 100/33 and Suliqua.

Another two news for Zealand Pharma A/S (NASDAQ:ZEAL) were briefly published by: Seekingalpha.com on June 11, 2018 with title “Your Daily Pharma Scoop: Zealand Dips, Eloxx Surges, Venetoclax Approved”. The other Streetinsider.com‘s article was titled “Zealand Pharma (ZEAL) Phase 3 Trial of Dasiglucagon Met Primary and Secondary Objectives” and published on June 08, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: